Evidence map›Paper›PMID 40097663›Full record

Trial reportNature medicine2025

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato, Konstantin Laktionov, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine and 13 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02511106 (A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy), which is not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02511106 phase3active not recruitingnot on this map

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).

TypeinterventionalSponsorAstraZenecaRan2015 to 2029Enrolled682ConditionsStage IB-IIIA Non-small Cell Lung CarcinomaArmsAZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Targeting ClassicalCancers · 2026
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Roy S Herbst *Medical Oncology and Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA. roy.herbst@yale.edu.ORCID http://orcid.org/0000-0003-2535-5847
Thomas John *Department of Medical Oncology and Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-3399-5342
Christian GrohéKlinik für Pneumologie, Evangelische Lungenklinik Berlin Buch, Berlin, Germany.
Jonathan W GoldmanDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4925-8243
Terufumi KatoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Konstantin LaktionovFederal State Budgetary Institution 'N. N. Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation, Moscow, Russia.
Laura BonannoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Marcello TiseoDepartment of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Margarita MajemDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9919-7485
Manuel DómineDepartment of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
Myung-Ju AhnDepartment of Hemato-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5740-9654
Dariusz M KowalskiDepartment of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID http://orcid.org/0000-0002-9452-3229
Maurice PérolDepartment of Medical Oncology, Léon-Bérard Cancer Center, Lyon, France.ORCID http://orcid.org/0000-0002-3296-423X
Virote SriuranpongDepartment of Medicine, Medical Oncology Unit, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Mustafa ÖzgüroğluDepartment of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Preetida BhetariyaOncology Data Science, Oncology R&D, AstraZeneca, Boston, MA, USA.
Aleksandra MarkovetsOncology Data Science, Oncology R&D, AstraZeneca, Boston, MA, USA.
Yuri RukazenkovLate-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Caitlin MuldoonBiometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
Jacqulyne RobichauxTranslational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8812-7054
Ryan HartmaierTranslational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7416-6036
Masahiro TsuboiDepartment of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. syylwu@live.cn.ORCID http://orcid.org/0000-0002-3611-0258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib-a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor-is recommended as adjuvant therapy for resected stage IB-IIIA epidermal growth factor receptor-mutated non-small-cell lung cancer, based on significant disease-free survival (DFS) and overall survival improvement shown in the previously reported phase 3 ADAURA trial. A trend toward an increased DFS event rate after completion of 3 years adjuvant treatment in ADAURA suggests that some patients may benefit from longer adjuvant osimertinib treatment. We therefore explored whether tumor-informed, circulating tumor DNA-based, molecular residual disease (MRD) could predict recurrence in an exploratory post hoc analysis of 220 patients (n = 112 osimertinib; n = 108 placebo) from ADAURA. MRD preceded imaging DFS events in this study by a median of 4.7 (95% confidence interval, 2.2-5.6) months. DFS and MRD event-free rate at 36 months was 86% versus 36% for patients in the osimertinib versus placebo groups (hazard ratio, 0.23 (95% confidence interval, 0.15-0.36)). In the osimertinib group, DFS or MRD events were detected in 28 (25%) patients; most events occurred following osimertinib cessation (19 of 28, 68%) and within 12 months of stopping osimertinib (11 of 19, 58%). At 24 months after osimertinib, the DFS and MRD event-free rate was 66%. In this study, MRD preceded DFS events in most patients across both arms. DFS and MRD event-free status was maintained for most patients during adjuvant osimertinib treatment and posttreatment follow-up, with most MRD or DFS events occurring after osimertinib treatment discontinuation or completion. MRD detection could potentially identify patients who may benefit from longer adjuvant osimertinib, although this requires clinical confirmation. ClinicalTrials.gov identifier: NCT02511106 .

Indexed as

AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm, ResidualAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansIndolesMaleMiddle AgedMutationAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID40097663
PMCPMC12176615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.